Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

SELL
$3.38 - $5.65 $1.24 Million - $2.08 Million
-368,000 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$5.06 - $8.77 $1.62 Million - $2.81 Million
-320,000 Reduced 46.51%
368,000 $2.03 Million
Q4 2021

Feb 14, 2022

BUY
$7.33 - $9.32 $1.38 Million - $1.75 Million
188,000 Added 37.6%
688,000 $5.86 Million
Q3 2021

Nov 15, 2021

BUY
$7.01 - $11.37 $102,570 - $166,365
14,632 Added 3.01%
500,000 $4.35 Million
Q2 2021

Aug 16, 2021

BUY
$9.4 - $16.85 $4.56 Million - $8.18 Million
485,368 New
485,368 $5.13 Million
Q2 2021

Aug 16, 2021

SELL
$9.4 - $16.85 $4.56 Million - $8.18 Million
-485,368 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$13.08 - $49.6 $6.35 Million - $24.1 Million
485,368 New
485,368 $7.79 Million
Q4 2020

Feb 16, 2021

SELL
$36.36 - $52.71 $8.37 Million - $12.1 Million
-230,307 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$22.61 - $38.9 $2.26 Million - $3.89 Million
100,000 Added 76.74%
230,307 $8.11 Million
Q2 2020

Aug 14, 2020

SELL
$13.87 - $28.44 $6.13 Million - $12.6 Million
-441,635 Reduced 77.22%
130,307 $3.17 Million
Q1 2020

May 15, 2020

BUY
$8.36 - $17.13 $3.95 Million - $8.08 Million
471,942 Added 471.94%
571,942 $8.9 Million
Q4 2019

Feb 14, 2020

BUY
$10.02 - $16.4 $1 Million - $1.64 Million
100,000 New
100,000 $1.59 Million

Others Institutions Holding IMVT

About Immunovant, Inc.


  • Ticker IMVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 129,077,000
  • Market Cap $3.55B
  • Description
  • Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...
More about IMVT
Track This Portfolio

Track Mangrove Partners Portfolio

Follow Mangrove Partners and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mangrove Partners, based on Form 13F filings with the SEC.

News

Stay updated on Mangrove Partners with notifications on news.